MERS: Difference between revisions
From WikiMD's Wellness Encyclopedia
No edit summary Tag: visualeditor-wikitext |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Middle East respiratory syndrome (MERS) | |||
| image = [[File:MERS-CoV_electron_micrograph3.jpg|alt=Electron micrograph of MERS-CoV]] | |||
| caption = Electron micrograph of MERS-CoV | |||
| field = [[Infectious disease]] | |||
| symptoms = [[Fever]], [[cough]], [[shortness of breath]] | |||
| complications = [[Pneumonia]], [[kidney failure]] | |||
| onset = 2 to 14 days after exposure | |||
| duration = Varies | |||
| causes = [[Middle East respiratory syndrome-related coronavirus]] (MERS-CoV) | |||
| risks = [[Travel]] to the [[Middle East]], contact with [[camels]] or infected individuals | |||
| diagnosis = [[Polymerase chain reaction]] (PCR) testing | |||
| differential = [[Influenza]], [[pneumonia]], [[SARS]] | |||
| prevention = Avoiding contact with camels, practicing good hygiene | |||
| treatment = Supportive care | |||
| prognosis = Varies; higher risk of severe disease in older adults and those with chronic conditions | |||
| frequency = Approximately 2,500 cases reported globally | |||
| deaths = Approximately 35% mortality rate | |||
}} | |||
Middle East respiratory syndrome; first tubercles described in Saudi Arabia in 2013. | Middle East respiratory syndrome; first tubercles described in Saudi Arabia in 2013. | ||
Most people confirmed to have MERS-CoV infection have had severe respiratory illness with symptoms of: | Most people confirmed to have MERS-CoV infection have had severe respiratory illness with symptoms of: | ||
* [[fever]] | * [[fever]] | ||
* [[cough]] | * [[cough]] | ||
* [[shortness of breath]] | * [[shortness of breath]] | ||
* [[diarrhea]] and [[nausea]]/[[vomiting]] in some | * [[diarrhea]] and [[nausea]]/[[vomiting]] in some | ||
==Risk factors== | ==Risk factors== | ||
Pre-existing conditions among people who got MERS have included | Pre-existing conditions among people who got MERS have included | ||
* [[diabetes]] | * [[diabetes]] | ||
* [[cancer]] | * [[cancer]] | ||
| Line 16: | Line 32: | ||
* chronic heart disease | * chronic heart disease | ||
* [[chronic kidney disease]] | * [[chronic kidney disease]] | ||
[[File:SARS-CoV-1 mammals as carriers.png|alt=SARS-CoV-1 mammals as carriers|thumb|SARS-CoV-1 mammals as carriers]] | [[File:SARS-CoV-1 mammals as carriers.png|alt=SARS-CoV-1 mammals as carriers|left|thumb|SARS-CoV-1 mammals as carriers]] | ||
==Symptom onset== | ==Symptom onset== | ||
* The symptoms of MERS start to appear about 5 or 6 days after a person is exposed, but can range from 2 to 14 days. | * The symptoms of MERS start to appear about 5 or 6 days after a person is exposed, but can range from 2 to 14 days. | ||
* Some infected people had mild symptoms (such as cold-like symptoms) or no symptoms at all. | * Some infected people had mild symptoms (such as cold-like symptoms) or no symptoms at all. | ||
<youtube> | <youtube> | ||
title='''{{PAGENAME}}''' | title='''{{PAGENAME}}''' | ||
movie_url=http://www.youtube.com/v/B93uZPvThKc | movie_url=http://www.youtube.com/v/B93uZPvThKc | ||
&rel=1 | &rel=1 | ||
| Line 31: | Line 46: | ||
height=600 | height=600 | ||
</youtube> | </youtube> | ||
==Transmission== | ==Transmission== | ||
* MERS-CoV, like other [[coronavirus]]es, likely spreads from an infected | * MERS-CoV, like other [[coronavirus]]es, likely spreads from an infected person’s respiratory secretions, such as through coughing. However, we don’t fully understand the precise ways that it spreads. | ||
* MERS-CoV has spread from ill people to others through close contact, such as caring for or living with an infected person. Infected people have spread MERS-CoV to others in healthcare settings, such as hospitals. | * MERS-CoV has spread from ill people to others through close contact, such as caring for or living with an infected person. Infected people have spread MERS-CoV to others in healthcare settings, such as hospitals. | ||
* Researchers studying MERS have not seen any ongoing spreading of MERS-CoV in the community. | * Researchers studying MERS have not seen any ongoing spreading of MERS-CoV in the community. | ||
* All reported cases have been linked to countries in and near the Arabian Peninsula. | * All reported cases have been linked to countries in and near the Arabian Peninsula. | ||
* Most infected people either lived in the Arabian Peninsula or recently traveled from the Arabian Peninsula before they became ill. | * Most infected people either lived in the Arabian Peninsula or recently traveled from the Arabian Peninsula before they became ill. | ||
* A few people have gotten MERS after having close contact with an infected person who had recently traveled from the Arabian Peninsula. | * A few people have gotten MERS after having close contact with an infected person who had recently traveled from the Arabian Peninsula. | ||
* The largest known outbreak of MERS outside the Arabian Peninsula occurred in the Republic of Korea in 2015 and was associated with a traveler returning from the Arabian Peninsula. | * The largest known outbreak of MERS outside the Arabian Peninsula occurred in the Republic of Korea in 2015 and was associated with a traveler returning from the Arabian Peninsula. | ||
[[File:SARS-CoV MERS-CoV genome organization and S-protein domains.png|alt=MERS-CoV genome organization|thumb|MERS-CoV genome organization]] | [[File:SARS-CoV MERS-CoV genome organization and S-protein domains.png|alt=MERS-CoV genome organization|left|thumb|MERS-CoV genome organization]] | ||
==Clinical Course== | ==Clinical Course== | ||
* The median incubation period for secondary cases associated with limited human-to-human transmission is approximately 5 days (range 2-14 days). | * The median incubation period for secondary cases associated with limited human-to-human transmission is approximately 5 days (range 2-14 days). | ||
* In MERS-CoV patients, the median time from illness onset to hospitalization is approximately 4 days. | * In MERS-CoV patients, the median time from illness onset to hospitalization is approximately 4 days. | ||
* In critically ill patients, the median time from onset to intensive care unit (ICU) admission is approximately 5 days, and median time from onset to death is approximately 12 days. | * In critically ill patients, the median time from onset to intensive care unit (ICU) admission is approximately 5 days, and median time from onset to death is approximately 12 days. | ||
* In one series of 12 ICU patients, the median duration of mechanical ventilation was 16 days, and median ICU length of stay was 30 days, with 58% mortality at 90 days. | * In one series of 12 ICU patients, the median duration of mechanical ventilation was 16 days, and median ICU length of stay was 30 days, with 58% mortality at 90 days. | ||
* Radiographic findings may include unilateral or bilateral patchy densities or opacities, interstitial infiltrates, consolidation, and pleural effusions. | * Radiographic findings may include unilateral or bilateral patchy densities or opacities, interstitial infiltrates, consolidation, and pleural effusions. | ||
* Rapid progression to acute respiratory failure, acute respiratory distress syndrome (ARDS), refractory hypoxemia, and extrapulmonary complications (acute kidney injury requiring renal replacement therapy, hypotension requiring vasopressors, hepatic inflammation, septic shock) has been reported. | * Rapid progression to acute respiratory failure, acute respiratory distress syndrome (ARDS), refractory hypoxemia, and extrapulmonary complications (acute kidney injury requiring renal replacement therapy, hypotension requiring vasopressors, hepatic inflammation, septic shock) has been reported. | ||
<youtube> | <youtube> | ||
title='''{{PAGENAME}}''' | title='''{{PAGENAME}}''' | ||
movie_url=http://www.youtube.com/v/aFPyYoGViZs | movie_url=http://www.youtube.com/v/aFPyYoGViZs | ||
&rel=1 | &rel=1 | ||
| Line 59: | Line 72: | ||
height=600 | height=600 | ||
</youtube> | </youtube> | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
* Laboratory findings at admission may include leukopenia, lymphopenia, thrombocytopenia, and elevated lactate dehydrogenase levels. | * Laboratory findings at admission may include leukopenia, lymphopenia, thrombocytopenia, and elevated lactate dehydrogenase levels. | ||
* Co-infection with other respiratory viruses and a few cases of co-infection with community-acquired bacteria at admission has been reported; nosocomial bacterial and fungal infections have been reported in mechanically-ventilated patients. | * Co-infection with other respiratory viruses and a few cases of co-infection with community-acquired bacteria at admission has been reported; nosocomial bacterial and fungal infections have been reported in mechanically-ventilated patients. | ||
* MERS-CoV virus can be detected with higher viral load and longer duration in the lower respiratory tract compared to the upper respiratory tract, and has been detected in feces, serum, and urine. | * MERS-CoV virus can be detected with higher viral load and longer duration in the lower respiratory tract compared to the upper respiratory tract, and has been detected in feces, serum, and urine. | ||
* Duration of MERS-CoV shedding in the respiratory tract is typically longer in more severely ill patients than mildly ill patients, and evidence of virus has been detected in survivors for a month or more after onset. | * Duration of MERS-CoV shedding in the respiratory tract is typically longer in more severely ill patients than mildly ill patients, and evidence of virus has been detected in survivors for a month or more after onset. | ||
* Limited data are available on the duration of extrapulmonary MERS-CoV shedding. | * Limited data are available on the duration of extrapulmonary MERS-CoV shedding. | ||
* ==Treatment== | * ==Treatment== | ||
* There is no specific antiviral treatment recommended for MERS-CoV infection. | * There is no specific antiviral treatment recommended for MERS-CoV infection. | ||
* Individuals with MERS often receive medical care to help relieve symptoms. | * Individuals with MERS often receive medical care to help relieve symptoms. | ||
* For severe cases, current treatment includes care to support vital organ functions. | * For severe cases, current treatment includes care to support vital organ functions. | ||
==Prevention== | ==Prevention== | ||
You can help reduce your risk of getting respiratory illnesses: | You can help reduce your risk of getting respiratory illnesses: | ||
| Line 80: | Line 90: | ||
* Clean and disinfect frequently touched surfaces and objects, such as doorknobs. | * Clean and disinfect frequently touched surfaces and objects, such as doorknobs. | ||
* If you are caring for or living with a person confirmed to have, or being evaluated for, MERS-CoV infection, see Interim Guidance for Preventing MERS-CoV from Spreading in Homes and Communities. | * If you are caring for or living with a person confirmed to have, or being evaluated for, MERS-CoV infection, see Interim Guidance for Preventing MERS-CoV from Spreading in Homes and Communities. | ||
{{Zoonotic viral diseases}} | {{Zoonotic viral diseases}} | ||
{{Viral systemic diseases}} | {{Viral systemic diseases}} | ||
Latest revision as of 04:33, 8 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC
| Middle East respiratory syndrome (MERS) | |
|---|---|
| |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Fever, cough, shortness of breath |
| Complications | Pneumonia, kidney failure |
| Onset | 2 to 14 days after exposure |
| Duration | Varies |
| Types | N/A |
| Causes | Middle East respiratory syndrome-related coronavirus (MERS-CoV) |
| Risks | Travel to the Middle East, contact with camels or infected individuals |
| Diagnosis | Polymerase chain reaction (PCR) testing |
| Differential diagnosis | Influenza, pneumonia, SARS |
| Prevention | Avoiding contact with camels, practicing good hygiene |
| Treatment | Supportive care |
| Medication | N/A |
| Prognosis | Varies; higher risk of severe disease in older adults and those with chronic conditions |
| Frequency | Approximately 2,500 cases reported globally |
| Deaths | Approximately 35% mortality rate |
Middle East respiratory syndrome; first tubercles described in Saudi Arabia in 2013.
Most people confirmed to have MERS-CoV infection have had severe respiratory illness with symptoms of:
Risk factors[edit]
Pre-existing conditions among people who got MERS have included
- diabetes
- cancer
- chronic lung disease
- chronic heart disease
- chronic kidney disease

Symptom onset[edit]
- The symptoms of MERS start to appear about 5 or 6 days after a person is exposed, but can range from 2 to 14 days.
- Some infected people had mild symptoms (such as cold-like symptoms) or no symptoms at all.
Transmission[edit]
- MERS-CoV, like other coronaviruses, likely spreads from an infected person’s respiratory secretions, such as through coughing. However, we don’t fully understand the precise ways that it spreads.
- MERS-CoV has spread from ill people to others through close contact, such as caring for or living with an infected person. Infected people have spread MERS-CoV to others in healthcare settings, such as hospitals.
- Researchers studying MERS have not seen any ongoing spreading of MERS-CoV in the community.
- All reported cases have been linked to countries in and near the Arabian Peninsula.
- Most infected people either lived in the Arabian Peninsula or recently traveled from the Arabian Peninsula before they became ill.
- A few people have gotten MERS after having close contact with an infected person who had recently traveled from the Arabian Peninsula.
- The largest known outbreak of MERS outside the Arabian Peninsula occurred in the Republic of Korea in 2015 and was associated with a traveler returning from the Arabian Peninsula.

Clinical Course[edit]
- The median incubation period for secondary cases associated with limited human-to-human transmission is approximately 5 days (range 2-14 days).
- In MERS-CoV patients, the median time from illness onset to hospitalization is approximately 4 days.
- In critically ill patients, the median time from onset to intensive care unit (ICU) admission is approximately 5 days, and median time from onset to death is approximately 12 days.
- In one series of 12 ICU patients, the median duration of mechanical ventilation was 16 days, and median ICU length of stay was 30 days, with 58% mortality at 90 days.
- Radiographic findings may include unilateral or bilateral patchy densities or opacities, interstitial infiltrates, consolidation, and pleural effusions.
- Rapid progression to acute respiratory failure, acute respiratory distress syndrome (ARDS), refractory hypoxemia, and extrapulmonary complications (acute kidney injury requiring renal replacement therapy, hypotension requiring vasopressors, hepatic inflammation, septic shock) has been reported.
Laboratory Findings[edit]
- Laboratory findings at admission may include leukopenia, lymphopenia, thrombocytopenia, and elevated lactate dehydrogenase levels.
- Co-infection with other respiratory viruses and a few cases of co-infection with community-acquired bacteria at admission has been reported; nosocomial bacterial and fungal infections have been reported in mechanically-ventilated patients.
- MERS-CoV virus can be detected with higher viral load and longer duration in the lower respiratory tract compared to the upper respiratory tract, and has been detected in feces, serum, and urine.
- Duration of MERS-CoV shedding in the respiratory tract is typically longer in more severely ill patients than mildly ill patients, and evidence of virus has been detected in survivors for a month or more after onset.
- Limited data are available on the duration of extrapulmonary MERS-CoV shedding.
- ==Treatment==
- There is no specific antiviral treatment recommended for MERS-CoV infection.
- Individuals with MERS often receive medical care to help relieve symptoms.
- For severe cases, current treatment includes care to support vital organ functions.
Prevention[edit]
You can help reduce your risk of getting respiratory illnesses:
- Wash your hands often with soap and water for at least 20 seconds, and help young children do the same. If soap and water are not available, use an alcohol-based hand sanitizer.
- Cover your nose and mouth with a tissue when you cough or sneeze, then throw the tissue in the trash.
- Avoid touching your eyes, nose, and mouth with unwashed hands.
- Avoid personal contact, such as kissing, or sharing cups or eating utensils, with sick people.
- Clean and disinfect frequently touched surfaces and objects, such as doorknobs.
- If you are caring for or living with a person confirmed to have, or being evaluated for, MERS-CoV infection, see Interim Guidance for Preventing MERS-CoV from Spreading in Homes and Communities.
| Infectious diseases – viral systemic diseases | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|



